Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant HAIP chemotherapy after resection of low-risk colorectal liver metastases
NL-OMON52926Phase 3Recruiting
- Sponsor
- Erasmus MC
- Start
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of floxuridine in colorectal cancer liver metastasis (CRLM) and colorectal cancer (CRC) (2 arms), sponsored by Erasmus MC. Primary endpoint: Progression-free survival. Started Aug 2018; status: recruiting.
02
Drugs
floxuridine
03
Conditions
colorectal cancer liver metastasis (CRLM)colorectal cancer (CRC)
Beyond the preview
Go deeper on NL-OMON52926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52926.